Study on Gene Therapy for Subjects with Severe Sickle Cell Disease (Bluebird HGB-210) (H-44293)
Description
Content
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease (Bluebird HGB-210)
This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.
AGE REQUIREMENTS: 2 Years to 50 Years
More information about this study can be found on clinicaltrials.gov at the following link: https://clinicaltrials.gov/ct2/show/NCT04293185?cond=NCT04293185&draw=2&rank=1
NCT#/ClinicalTrials.gov ID: NCT04293185
Contact
Phone 1: 832–824–4881
IRB: H-44293
Status:
Active
Created:
